



LIST OF POSTERS

Poster viewing 2 (P001-P119)

P001

Granulocyte-macrophage colony-stimulating factor improves mucosal repair during active dextran sulfate sodium-induced colitis

E. Bernasconi, L. Favre, D. Bachmann, H. Bouzourene, E. Croze, S. Velichko, J. Parkinson, P. Michetti, D. Velin (Lausanne, Switzerland)

P002

Sero-reactivity to microbial components in Crohn's disease is associated with ileal involvement, non-inflammatory disease behaviour and NOD2/CARD15 genotype, but not response to medical therapy or risk for surgery

M. Papp, I. Altorjay, G.L. Norman, K. Palatka, G. Lakos, S. Fischer, L. Lakatos, L. Bene, T. Molnar, Z. Tulassay, P. Miheller, P.L. Lakatos (Budapest, Hungary)

P003

Early surgery in Crohn's disease

A. Aratari, C. Papi, G. Leandro, A. Viscido, L. Capurso, R. Caprilli (Rome, Italy)

P004

Mesalamine and post-operative recurrence in Crohn's disease: a retrospective long term follow-up study

A. Aratari, C. Papi, G. Leandro, A. Viscido, L. Capurso, R. Caprilli (Rome, Italy)

P005

High association between work productivity, daily activities and clinical endpoints in Crohn's disease: data from PRECiSE 2

M. Brown, O. Ø. Thomsen, O. Purcaru, S. Schreiber (Slough, United Kingdom)

P006

Infliximab therapy in ulcerative colitis: systematic review and meta-analysis

J.P. Gisbert, Y. Gonzalez-Lama, J. Mate (Madrid, Spain)

P007

Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients

J.P. Gisbert, P. Niño, L. Rodrigo, C. Cara, L.G. Guijarro (Madrid, Spain)

P008

6-thioguanine nucleotide (6-TGN) concentrations and efficacy of azathioprine (AZA) and mercaptopurine (MP) in inflammatory bowel disease: systematic review and meta-analysis

J.P. Gisbert, Y. Gonzalez-Lama, J. Mate (Madrid, Spain)

P009

Thiopurine-induced liver injury in patients with inflammatory bowel disease (IBD): a systematic review

J.P. Gisbert, Y. Gonzalez-Lama, J. Mate (Madrid, Spain)

P010



5-aminosalicylates (5-ASAs) and renal function in inflammatory bowel disease (IBD): a systematic review

J.P. Gisbert, Y. Gonzalez-Lama, J. Mate (Madrid, Spain)

P011

Certolizumab pegol improves work productivity and the ability to perform daily activities in patients with Crohn's disease: data from PRECiSE 2

B. Feagan, M. Brown, L. Gerlier, S. Schreiber (Slough, United Kingdom)

P012

CD-68 positive cells in buccal mucosa as diagnostic marker for IBD

B. Mijandrušić-Sinèić, M. Ilić-Tomaš, D. Kovač, M. Juretić, M. Belušić-Gobić, A. Lekić, R. Cerović, D. Štimac (Rijeka, Croatia)

P013

Discrimination of IBD versus IBS: accuracy of Fecal Leucocyte Markers is improved when combined with IBD Antibody Panels

A. Schoepfer, M. Trummler, P. Seeholzer, B. Seibold-Schmid, F. Seibold (Bern, Switzerland)

P014

Esophageal strictures in Eosinophilic Esophagitis: Dilation is an effective and safe alternative after failure of topical corticosteroids

A. Schoepfer, J. Gschossmann, F. Seibold, U. Scheurer, A. Straumann (Bern, Switzerland)

P015

Thalidomide in luminal and fistulising Crohn's disease resistant to standard therapies

S. Plamondon, S.C. Ng, M.A. Kamm (London, United Kingdom)

P016

Recurrent prolonged antigen encounters are necessary for 6-MP induced clonal deletion of antigen-specific memory T-cells in vivo

S. Ben-Horin, I. Goldstein, Z. Yerushalmi, O. Picard, E. Fudim, I. Barshack, A. Lang, Y. Goldschmid, S. Bar Meir, Y. Chowers (Ramat-Gan, Israel)

P017

Suspected acute ileitis. A prospective diagnostic protocol

E. Garrido, A. López San Román, M.A. Rodríguez-Gandía, M. Rivero, V.F. Moreira, J.R. Foruny, J.M. Milicua (Madrid, Spain)

P018

Certolizumab Pegol is effective in patients regardless of CRP level and disease duration: data from PRECiSE 2

J.F. Colombel, S.B. Hanauer, W.J. Sandborn, J. Panes, S. Schreiber (Lille, France)

P019

Subcutaneous Certolizumab Pegol is effective in patients with prior Infliximab exposure, or concomitant immunosuppressant or glucocorticoid treatment: data from PRECiSE 2

J.F. Colombel, S. Hanauer, W. Sandborn, J. Panes, S. Schreiber (Lille, France)

P020

Certolizumab Pegol 400 mg every 4 weeks improved health-related quality of life in patients with Crohn's disease in PRECiSE 2

B. Feagan, G. Coteur, D. Keininger, S. Schreiber (London, Canada)

P021



Subcutaneous Certolizumab Pegol is well tolerated by patients with active Crohn's disease: results from two Phase III studies (PRECiSE 1 and 2)

S. Schreiber, B.G. Feagan, S.B. Hanauer, P. Rutgeerts, W.J. Sandborn (Kiel, Germany)

P022

Patients with Crohn's disease reported improved health status following treatment with Certolizumab Pegol 400 mg: data from PRECiSE 2

B. Feagan, G. Coteur, D. Keininger, S. Schreiber (Braine-L'Alleud, Belgium)

P023

Infliximab therapy of renal AA amyloidosis complicating Crohn's disease (CD)

M.A. Denis, A. Persu, P. Hoang, M. Jadoul, F. Zerbib, O. Dewit, R. Fiasse (Bruxelles, Belgium)

P024

Nutritional status in patients with Crohn's disease (CD) in the era of biologic therapy: a case-control study

C.S. Guerreiro, A. Costa, A. Miranda, L. Tavares, P.M. Santos, J.P. Silva, I. Claro, M. Cravo (Lisboa, Portugal)

P025

Exclusion diets in patients with Crohn's disease (CD) predispose to nutritional deficiencies

C.S. Guerreiro, A. Costa, A. Miranda, L. Tavares, P.M. Santos, J.P. Silva, I. Claro, M. Cravo (Lisboa, Portugal)

P026

Infliximab improves splenic function and restores immunoglobulin M memory B cell pool in Crohn's disease patients

A. Di Sabatino, M.M. Rosado, P. Cazzola, P. Biancheri, L. Rovedatti, R. Carsetti, G.R. Corazza (Pavia, Italy)

P027

Functional modulation of Crohn's disease myofibroblasts by anti-TNF antibodies

A. Di Sabatino, S.L.F. Pender, C.L. Jackson, J. Gordon, L. Picariello, G. Monteleone, F. Tonelli, G.R. Corazza, T.T. MacDonald (Pavia, Italy)

P028

Open-label Infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response

Y. Gonzalez-Lama (Madrid, Spain)

P029

A new 'Calprotectin POC device' correlates with ELISA and separates between endoscopic assessed mucosal healing and active Ulcerative Colitis

A. Roseth, J. Wasiluk, I. Dale, M. Fagerhol (Oslo, Norway)

P030

Long-term effectiveness of Azathioprine (AZA) for Crohn's Disease (CD) and Ulcerative Colitis (UC)

J. Gisbert, P. Niño, C. Cara, M. Bourgois, L. Rodrigo (Madrid, Spain)

P031

Expression of toll-like receptors 2, 3 and 4 in children with inflammatory bowel disease

G. Veres, B. Szebeni, M. Mraz, A. Dezsőfi, A. Vannay, B. Vásárhelyi, E. Majorova, A. Arato (Budapest, Hungary)



P032

Multi-gene approach to discriminate for ulcerative colitis, Crohn's disease and irritable bowel syndrome

P. von Stein, N. Kouznetsov, A. Gielen, Å. Öst, O. von Stein, R. Löfberg (Stockholm, Sweden)

P033

Azathioprine/6-mercaptopurine (AZA/6-MP) reduces the risk of intestinal re-operation in Crohn's disease (CD)

P. Papay, E. Ho, W. Reinisch, W. Miehsler, H. Vogelsang, G. Novacek (Vienna, Austria)

P034

Psychological counselling may improve the natural history of inflammatory bowel disease (IBD)

M. Wahed, D. Rampton, M. Corser (London, United Kingdom)

P035

Fecal S100A12 as non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome

D. Foell, J. Langhorst, T. Kaiser, H. Wittkowski, A. Rueffer, G. Dobos, J. Roth (Muenster, Germany)

P036

Long-term follow-up with Adacolumn®Apheresis re-treatment in patients with chronically active Inflammatory Bowel Disease (IBD) refractory to conventional treatment

P. Karlén, A. Lindberg, I. Löfberg (Stockholm, Sweden)

P037

Results of the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) patient survey: prevalence and impact on quality of life

R. Mitchell, S. Ghosh (Bornemouth, United Kingdom)

P038

Infliximab is associated with decreased healthcare costs in patients with Crohn's disease

C. Sarp, C. de la Coba, M.A. Casado, J.M. Morales, B. Otero (Gijón (Asturias), Spain)

P039

Effect of Infliximab on circulating levels of Leptin, Adiponectin and Resistin in inflammatory bowel disease

I. Koutroubakis, K. Karmiris, C. Xidakis, M. Polychronaki, E. Kouroumalis (Heraklion, Crete, Greece)

P040

Development of an educational nutritional (cooking) program for Crohn's disease patients

R. Polak, E. Goldin, O. Sasson, E. Israeli (Jerusalem, Israel)

P041

Quality of life after restorative proctocolectomy for ulcerative colitis

M. Tariverdian, C. Leowardi, U. Hinz, T. Welsch, J. Schmidt, P. Kienle (Heidelberg, Germany)

P042

Pouch surgery offers a good quality of life despite ongoing problems

M. Bortlik, D. Duricova, M. Lukas (Prague, Czech Republic)

P043

Budesonide MMX is efficient and safe in patients with active left-sided ulcerative colitis

G. D'Haens, Á. Kovács, P. Vergauwe, J. Lonovics, Y. Bouhnik, W. Weiss, H. Brunner, A. Lavergne-Slove, A. Di Stefano, P. Marteau (Bonheiden, Belgium)



P044

Czech Registry of IBD patients - a first report of its existence

M. Bortlik, M. Lukas, J. Stehlik (Prague, Czech Republic)

P045

The use of Azathioprine for the treatment of Inflammatory Bowel Diseases in clinical practice: a multicenter, retrospective study

S. Saibeni, T. Virgilio, L. Spina, R. D'Inca, M. Paccagnella, A. Bortoli, M. Peli, R. Sablich, E. Colombo, C.M. Girelli, M. Vecchi (San Donato Milanese (Mi), Italy)

P046

Pregnancy in IBD patients

R. Donoval, M. Bortlik, A. Parizek, M. Lukas (Prague, Czech Republic)

P047

Safety and efficacy of oral, colonic-release, low molecular weight heparin-MMx™ for the treatment of mild to moderate left-sided ulcerative colitis: preliminary report of a pilot study

L. Spina, S. Saibeni, L. Pastorelli, C. Signorelli, C. Ciscato, R. de Franchis, L. Moro, R. Villa, R. Bozzella, G. Celasco, M. Vecchi (San Donato Milanese (Mi), Italy)

P048

A clinical trial on absorption and N-acetylation of oral and rectal mesalazine

K. Dilger, D. Trenk, M. Rössle, M. Cap, A. Zähringer, V. Wacheck, C. Remmler, I. Cascorbi, W. Kreisel, G. Novacek (Vienna, Austria)

P049

Granulocyte-Monocyte-Apheresis: predictors of clinical remission in ulcerative colitis patients

V. D'Ovidio, A. Aratari, D. Guagnozzi, R. Caprilli (Roma, Italia)

P050

withdrawn

P051

Wireless capsule endoscopy versus small intestine contrast ultrasonography for assessing the postoperative recurrence of Crohn's disease: a prospective longitudinal study

L. Biancone, E. Calabrese, C. Petruzzello, S. Onali, F. Zorzi, M. Cossignani, G. Sica, F. Pallone (Rome, Italy)

P052

Risk factors for initial surgery in pediatric patients with Crohn's disease: a population-based cohort study

G. Vernier-Massouille, M. Baldé, C. Gower-Rousseau, F. Brazier, V. Merle, R. Marti, E. Lerebours, J.L. Dupas, A. Cortot, D. Turck, J.L. Salomez, J.F. Colombel (Lille, France)

P053

Clinical impact of double-balloon enteroscopy in Crohn's disease patients

P.B.F. Mensink, M.J.M. Groenen, H.R. van Buuren, E.J. Kuipers, J. van der Woude (Rotterdam, The Netherlands)

P054

Health-related quality of life (HRQOL) in patients with diabetes mellitus compared with patients with inflammatory bowel disease and general population norm

L.P. JÃ,rgensen, T. Bernklev, B. Mella, J. Jahnsen, M. Vatn, J. Sauar, B. Moum (Fredrikstad, Norway)



P055

Epidemiology, clinical presentation and outcome in ulcerative colitis: observation from urban population during 10 years period

Y. Marakhouski, J. Hargun, K. Marakhouski (Minsk, Belarus)

P056

Number needed to treat with MMX mesalazine for one patient with mild-to-moderate ulcerative colitis to achieve remission

S. Schreiber, W. Sandborn, G. Lichtenstein, M. Kamm, K. Barrett, R. Joseph (Kiel, Germany)

P057

MMX mesalazine is an effective treatment for men and women with mild-to-moderate, active ulcerative colitis

M. Gassull, G. Lichtenstein, W. Sandborn, M. Kamm, K. Barrett, R. Joseph (Badalona, Spain)

P058

Levels of depression and anxiety in the patients with IBD

D. Štimac, M. Tkalèiæ, A. Pokrajac Bulian, I. Krznariæ Zrniæ, T. Guina, B. Mijandrušic Sincic (Rijeka, Croatia)

P059

MMX mesalazine is an effective treatment for active, mild-to-moderate UC regardless of prior 5-ASA use: a pooled analysis of two placebo-controlled, phase III trials

M. Kamm, G. Lichtenstein, W. Sandborn, K. Barrett, R. Joseph (Harrow, United Kingdom)

P060

Open-label Infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response

Y. González-Lama (Madrid, Spain)

P061

6-Thioguanine Nucleotide (6-TGN) concentrations and efficacy of Azathioprine (AZA) and Mercaptopurine (MP) in inflammatory bowel disease: The METAZA study

J. Gisbert (Madrid, Spain)

P062

Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy

Y. Zabana, E. Domènech, A. Lopez-Sanroman, B. Beltran, J.L. Cabriada, C. Saro, R. Aramendiz, D. Ginard, J. Hinojosa, J.P. Gisbert, M.A. Gassull (Badalona, Spain)

P063

Decreased endoscopic evidence of inflammation in patients with Crohn's disease after long-term therapy with Infliximab: a single-centre experience

A. Papa, I. De Vitis, S. Guglielmo, F. Scaldaferri, L. Guidi, I. Roberto, G. Mocci, M. Bonizzi, G. Andrisani, C. Felice, G. Fedeli, A. Gasbarrini (Rome, Italy)

P064

Standard dose low molecular weight heparin prophylaxis for deep venous thrombosis after surgery for Inflammatory Bowel Disease

C. Ruffolo, F. Pilon, V. Pengo, G. Romanato, M. Scarpa, R. Marin, T. Filosa, S. Basato, M. Bertin, L. Polese, E. Manzato, I. Angriman (Padova, Italy)

P065

Effect of 5-aminosalicylates (5-ASAs) on renal function in patients with inflammatory bowel disease (IBD): 4-year follow-up study



J. Gisbert, M. Luna, Y. Gonzalez-Lama, J. Mate (Madrid, Spain)

P066

Long-term follow-up of patients after total proctocolectomy with definitive ileostomy (TCP-DI) for Crohn's Disease (CD)

A. Amiot, J.M. Gornet, A. Martine, M. Simon, F. Ben Hriz, M. Nachury, M. Allez, M. Lemann (Paris, France)

P067

Natalizumab induces sustained response and remission in Crohn's patients with previous infliximab failure: results from the encore trial

M. Spehlmann, B. Feagan, R. Fedorak, B. Lashner, R. Panaccione, D. Present, P. Rutgeerts, W. Sandborn, M. Volfova, D. Wolf, S. Targan (Hamburg, Germany)

P068

Natalizumab maintains remission for 2 years in patients with moderately to severely active Crohn's disease and in those with prior Infliximab exposure: results from an open-label extension study

G. D'Haens, F. Baert, P. Rutgeerts, R. Panaccione (Bonheiden, Belgium)

P069

A single centre experience of Adalimumab treatment in patients with luminal and fistulizing Crohn's disease (CD): do antibodies to Infliximab (ATIs) affect clinical outcome?

R.L. West, E.J. Kuipers, P. van der Toorn, E. Buster, P.B.F. Mensink, G.J. Wolbink, C.J. van der Woude (Rotterdam, The Netherlands)

P070

Wireless capsule endoscopy in Crohn's disease: clinical relevance of upper GI lesions and feasibility 2 years after ILEO-colonic resection

L. Biancone, C. Petruzzello, E. Calabrese, G. Del Vecchio Blanco, S. Onali, M. Cossignani, G. Sica, F. Pallone (Rome, Italy)

P071

Risk factors associated with small bowel adenocarcinoma in Crohn's Disease : a case-control study

G. Piton, J. Cosnes, E. Monnet, L. Beaugerie, G. Savoye, G. Cadiot, B. Flourie, M. Lemann, J.F. Colombel, P. Marteau, F. Carbonnel (Besançon, France)

P072

Ten years experience with Side to Side Isoperistaltic Strictureplasty (SSIS) in small bowel Crohn's disease

F. Tonelli, M. Fazi, F. Ficari, G. Canonico, F. Giudici (Firenze, Italy)

P073

Adequately dosed 6-TG use in chronic intestinal inflammation is not associated with nodular regenerative hyperplasia: a series of 73 liver biopsies

B. Jharap, C.J.J. Mulder, G. den Hartog, B.D. Westerveld, L.G.J.B. Engels, D.J. de Jong, A.A. van Bodegraven, N.K.H. de Boer (Amsterdam, The Netherlands)

P074

Gastroesophageal reflux disease and its influence on intensification of ailments in patients with Crohn's disease

D. Wasko-Czopnik, L. Paradowski (Wrocław, Poland)

P075



Chemical stability of thiopurine metabolites in erythrocytes during 6-mercaptopurine and azathioprine treatment

P. de Graaf, R.M. Vos, N.K.H. de Boer, A. Sinjewel, B. Jharap, A.I. Veldkamp, A.A. van Bodegraven (Amsterdam, The Netherlands)

P076

Changes in salivary components in patients with Crohn disease

D. Wasiko-Czopnik, U. Kaczmarek, E. Soltan, L. Paradowski (Wroclaw, Poland)

P077

High circulating glucocorticoid bioactivity in an early phase of steroid therapy may indicate steroid dependent disease in IBD

M.K. Vihinen, T. Raivio, M. Verkasalo, O.A. Jänne, K.L. Kolho (Helsinki, Finland)

P078

Erythrocytes-mediated delivery of dexamethasone in patients with mild to moderate ulcerative colitis refractory to mesalamine. A randomised-controlled study

F. Bossa, A. Latiano, L. Rossi, M. Magnani, E. De Santo, O. Palmieri, T. Latiano, G. Corritore, A. Andriulli, V. Annese (San Giovanni Rotondo (Fg), Italy)

P079

Implication of Bcl-2 family proteins in the induction of Jurkat T lymphocyte apoptosis by the main n-3 fatty acids present in fish oil Docosahexaenoic and Eicosapentaenoic acid

T.J. Hommes, A. Giros, X. Llor, E. Pons, J. Fernandez-Morales, R.M. Xicola, M.A. Gassull (Badalona, Barcelona, Spain)

P080

Maintenance infliximab treatment for Crohn's disease over 54 weeks: our experience

M. Principi, D. Antonicelli, A. Pastorelli, A. Pisani, A. Di Leo, A. Francavilla (Bari, Italy)

P081

Treatment of ulcerative colitis with a combination of Lactobacillus rhamnosus and Lactobacillus acidophilus. Results of a randomised, double-blind, and placebo controlled trial

L. Klinge, J. Kjeldsen, L.A. Chriatensen, J.F. Dahlerup, M. Tvede, K. Lauritsen (Odense C, Denmark)

P082

Rituximab and ulcerative colitis: an unexpected beneficial collateral effect of lymphoma treatment

C. Mottet, V. Kessler, C. Felley, P. Michetti (Lausanne, Switzerland)

P083

Local injection of infliximab in Crohn's disease recurrence: a pilot prospective longitudinal study in the long-term

L. Biancone, M. Cretella, C. Petruzzello, C. Tosti, S. Onali, E. Calabrese, G. Sica, F. Pallone (Rome, Italy)

P084

Severity of Crohn's disease recurrence after ILEO-Colon resection: correlation between endoscopic score and sonographic findings

E. Calabrese, C. Petruzzello, S. Onali, G. Sica, M. Cossignani, F. Pallone, L. Biancone (Rome, Italy)

P085

Visilizumab for the treatment of subjects with intravenous steroid-refractory ulcerative colitis (IVSR-UC): Short and long-term disease response similar over multiple dose levels



D.C. Baumgart, S.R. Targan, B. Salzberg, L. Mayer, D. Hommes, U. Mahadevan, W. Reinisch, S. Plevy, A. Dignass, G. Van Assche, T. Pearce (Berlin, Germany)

P086

Therapeutic efficacy against murine DSS-induced colitis of two gene transfer vectors inducing generalized IL-10 overexpression.

C. Romero, J.F. Burgueño, J. Boada, F.X. Blasco, J.C. Perales, A. Río, M. Chillón, M.A. Gassull, E. Fernández (Bellaterra, Barcelona, Spain)

P087

Biosafety and biodistribution of chimeric adenoviruses to the gastrointestinal tract: a new approach to selective gene delivery to the intestine

C. Romero, E. Rodríguez, J.F. Burgueño, M. Ferrer, H. Hamada, A. Río, M. Chillón, M.A. Gassull, E. Fernández (Bellaterra, Barcelona, Spain)

P088

Colectomy rates after infliximab for refractory ulcerative colitis and predictive factors

M. Ferrante, S. Vermeire, M. Noman, F. Schnitzler, H. Fidder, G. Godefroidis, G. Van Assche, I. Hoffman, X. Bossuyt, P. Rutgeerts (Leuven, Belgium)

P089

Clinical and endoscopic outcome after the first corticosteroid course in newly diagnosed ulcerative colitis: a 5-years follow-up inception cohort study

S. Ardizzone, A. Cassinotti, P. Maria Chiara, P. Duca, A. Massari, G. Manes, V. Imbesi, S. Greco, E. Radice, E. Bareggi, G. Maconi, G. Bianchi Porro (Milan, Italy)

P090

Time to diagnosis in IBD patients belonging to a self-help group

G. Prinz, G. Novacek, H. Vogelsang, F. Schiener, C. Gmeinder, H. Ulmer, W. Reinisch (Vienna, Austria)

P091

IBD and lipid parameters: role of inflammation

G. Romanato, M. Scarpa, I. Angriman, R. Marin, C. Ruffolo, S. Basato, S. Zannoni, S. Zambon, T. Filosa, F. Pilon, L. Polese, E. Manzato (Padova, Italy)

P092

Autologous stem cell transplantation in moderate-severe refractory Crohn's disease: the Milan experience without CD 34+ cell selection

A. Cassinotti, S. Ardizzone, C. Annaloro, F. Onida, D. Trabattoni, A. Della Volpe, C. Vener, G. Maconi, S. Greco, G. Lambertenghi Delilieri, M. Clerici, G. Bianchi Porro (Milan, Italy)

P093

Restorative proctocolectomy for ulcerative colitis: impact on lipid metabolism and on tissutal and serum fatty acids

M. Scarpa, G. Romanato, E. Manzato, C. Ruffolo, R. Marin, S. Basato, S. Zannoni, S. Zambon, T. Filosa, F. Pilon, L. Polese, I. Angriman (Padova, Italy)

P094

Clinical, surgical and genetic risk factors for development of pouchitis following IPAA for ulcerative colitis

M. Ferrante, S. Declerck, T. Koopman, M. Pierik, P. Rutgeerts, G. Van Assche, A. D'Hoore, F. Penninckx, S. Vermeire (Leuven, Belgium)

P095



Long-term safety of azathioprine treatment in inflammatory bowel disease: results from a single referral center

K. Katsanos, M. Ferrante, H. Fidder, L. Henckaerts, D. Christodoulou, G. Van Assche, E. Tsianos, S. Vermeire, P. Rutgeerts (Ioannina, Greece)

P096

Lipid and phospholipid profile six months after ileo-colonic resection for Crohn's disease

G. Romanato, M. Scarpa, C. Ruffolo, R. Marin, S. Zannoni, S. Zambon, S. Basato, T. Filosa, F. Pilon, I. Angriman, E. Manzato (Padova, Italy)

P097

Natural history of cytomegalovirus infection in a cohort of patients diagnosed with moderate - severe ulcerative colitis

V. Criscuoli, M.R. Rizzuto, E. Gallo, M.C. Renda, A. Orlando, L. Montalbano, M. Cottone (Palermo, Italy)

P098

Fertility and sexual activity disorders in male patients with Inflammatory Bowel Disease

D. Checchin, A. Garolla, M. Lisiero, M. Martinato, R. D'Inca, C. Foresta, G.C. Sturniolo (Padua, Italy)

P099

Post operative Crohn's disease: The role of faecal lactoferrin in detecting clinical relapse after ileocaecal resection and measurement of faecal ASCA

M.K. Mohiuddin, J. Gicquel, J. Robson, C. Todhunter, J. Hanson, J. Mansfield (Newcastle, United Kingdom)

P100

Angiogenic factors VEGF-A, VEGF-C and midkine are elevated in flare and remission of ulcerative colitis and Crohn's disease

K. Blachut, M. Krzystek-Korpacka, M. Matusiewicz, P. Petryszyn, I. Kustrzeba-Wojcicka, T. Banas, L. Paradowski (Wroclaw, Poland)

P101

Oral calcium and vitamin D supplementation helps maintain bone mass and reduce bone turnover markers in patients with Inflammatory Bowel Disease. A randomized, double blinded, placebo controlled trial

P. Marden, D. Robertson, A. Bhalla, A. Holdaway, W. Fickling (Bath, United Kingdom)

P102

Thyroid disorders in a population of Ulcerative Colitis (UC) patients

G. Casella, E. De Marco, C. Monti, C.A. Buda, V. Baldini (Desio (Milan), Italy)

P103

Quantitative expression of CD64 on polymorphonuclear neutrophils: a new diagnostic tool in IBD

W. Tillinger, R. Jilch, U. Köller, N. Zwerina, H. Brunner (Vienna, Austria)

P104

The role of anorectal manometry in ulcerative colitis patients after restorative proctectomy

R. Kempinski, W. Bednarz, K. Blachut, L. Paradowski (Wroclaw, Poland)

P105

Surgery at diagnosis of Crohn's disease reduces the need for steroids and immunomodulators

G. Latella, A. Cocco, E. Angelucci, G. Fiorino, A. Viscido, S. Bacci, R. Caprilli (L'Aquila, Italy)



P106

5-Aminosalicylic acid (5-ASA)-mediated block of colon cancer cell growth is associated with degradation of CDC25A and accumulation of cells in S-phase

C. Stolfi, D. Fina, R. Caruso, F. Caprioli, M.C. Fantini, I. Peluso, A. Rizzo, F. Andrei, S. Bellinvia, F. Pallone, G. Monteleone (Rome, Italy)

P107

Benign intracranial hypertension and inflammatory bowel disease. A new extraintestinal manifestation or an adverse effect of therapy?

L. Crespo Pérez, A. López San Román, F. Martinez Silva, E. Marín Alcolado, X.A. García Aguilera, D. Boixeda de Miquel, V. Moreira Vicente (Alcorcon (Madrid), Spain)

P108

Visilizumab therapy in subjects with moderate-to-severe, refractory Crohn's disease

D.W. Hommes, S.R. Targan, A. Dignass, D.C. Baumgart, L. Mayer, L. Zhang, K. Wilson, T. Pearce (Fremont, USA)

P109

Dose-dependent influence of 5-ASA on thiopurine metabolism

N. de Boer, D. Wong, P.M. Hooymans, B. Jharap, P. de Graaf, C.J.J. Mulder, L.G.J.B. Engels, A.A. van Bodegraven (Amsterdam, The Netherlands)

P110

Cytomegalovirus and Epstein-Barr virus primo infections in patients with inflammatory bowel disease

M. Simon, M. Nachury, D. Parlier, V. Pacault, J.M. Gornet, J. M. Molina, M. Lemann, M. Allez (Paris, France)

P111

Contrast-enhanced ultrasound in the diagnosis of intraabdominal inflammatory masses complicating Crohn's disease. A prospective comparison with computed tomography

G. Maconi, E. Radice, C. Bezzio, S. Greco, F. Calliada, A. Norsa, G. Franceschelli, M. Scabini, S. Ardizzone, E. Bareggi, A. Russo, G. Bianchi Porro (Milan, Italy)

P112

Transcutaneous perianal ultrasound in the detection of perianal, anovulvar and rectovaginal fistulae in Crohn's disease

G. Maconi, S. Ardizzone, S. Greco, E. Radice, E. Bareggi, C. Bezzio, A. Cassinotti, G. Bianchi Porro (Milan, Italy)

P113

Short-term Adalimumab therapy improves quality of life in patients who had failed Infliximab therapy: results from the GAIN trial

E.V. Loftus, J.F. Colombel, P. Rutgeerts, G.R. D'Heans, R.A. Enns, P.M. Mulani, P.F. Pollack, W.J. Sandborn (Parsippany, Usa)

P114

Adalimumab safety in Crohn's disease: A sub-analysis of immunosuppressant and steroid use in the CHARM trial

J.F. Colombel, W.J. Sandborn, W. Reinisch, S.B. Hanauer, P. Rutgeerts, J. Li, P.F. Pollack (Parsippany, Usa)

P115

Long-term episodic Infliximab treatment in Crohn's Disease. A Danish Crohn Colitis database study



N. Pedersen, S. Caspersen, C. Mortensen, M. Elkjær, L. Riis, V. Wewer, P. Munkholm
(Taastrup, Denmark)

P116

PENTASA (Mesalazine) once or twice daily for the maintenance of remission of Ulcerative Colitis : demographic and baseline data for a 12 month single blind randomised controlled trial

A. Dignass, T. Stijnen, M. Mross, S. Vermeire, H. Veerman, A. Bhatt (, Switzerland)

P117

The understanding where to perform the bowel resection in Crohn's Disease (CD) surgery

P. Tonelli, M. Lucchese, P. Baccarini, F. Pedica, A. Valeri (Firenze, Italy)

P118

Infliximab as rescue therapy in acute severe UC: a survey of the Scottish Society of Gastroenterology (SSG)

C.W. Lees, D. Heys, A.G. Shand, I.D. Penman, K.R. Palmer, C.L. Noble, C. Mowat, H. Jafferbhoy, R. Boulton-Jones, A. Williams, H. Gillett, C. Evans, J. Todd, N. Church, K. Vaidya, J. Rose, I.D.R. Arnott, J. Satsangi (Edinburgh, United Kingdom)

P119

Gene expression profiling to predict the response of infliximab in patients with UC

I. Arjis, L. Van Lommel, K. Van Steen, G. De Hertogh, F. Schuit, K. Geboes, G. Van Assche, S. Vermeire, P. Rutgeerts (Leuven, Belgium)

Poster viewing 1 (P120-P200)

P120

The ATP-binding Cassette Transporter ABCG2 (BCRP) and ABCB1 (MDR1) variants are not associated with disease susceptibility, disease phenotype, response to medical therapy or need for surgery in Hungarian patients with Inflammatory Bowel Diseases

P.L. Lakatos, S. Fischer, L. Lakatos, A. Kovacs, T. Molnar, I. Altorjay, M. Papp, A. Szilvasi, Z. Tulassay, J. Osztoivits, J. Papp, P. Demeter (Budapest, Hungary)

P121

NOD2/CARD15 and TNF-alfa genes polymorphism in Lithuanian patients with inflammatory bowel disease

L. Kupcinskis, A. Zvirbliene, G. Kiudelis, S. Schreiber, R. Kwiatkowski (Kaunas, Lithuania)

P122

Natural history of inflammatory bowel disease in patients with primary sclerosing cholangitis: our experience

D. Bojic, M. Protic, P. Svorcan, B. Bojic, S. Djorovic, B. Dapcevic, N. Jojic (Belgrade, Serbia)

P123

A functional promoter polymorphism in CARD15 associated with Crohn's disease

D. Laukens, M. Loos, S. Bogaert, H. Peeters, J. Del-Favero, M. De Vos (Gent, Belgium)

P124

Transcription factors SOX2 and PDX-1 in ulcerative colitis and associated neoplasia - are they related to gastric apomucin expression and involved in carcinogenesis?

P. Borralho Nunes, A. Vieira, J. Freitas, A. Coias, C. Carneiro, P. Chaves (Almada, Portugal)



P125

Aberrant gastric apomucin in ulcerative colitis and associated neoplasia - an immunohistochemical demonstration

P. Borralho Nunes, A. Vieira, J. Freitas, P. Chaves, J. Soares (Almada, Portugal)

P126

Immunohistochemical expression of p53, Cdx2 and beta-catenin in inflammatory bowel disease (IBD)-associated, compared to sporadic, colorectal cancer: further evidence for different carcinogenic pathways.

C. Laurent, M. Svrcek, J.F. Fléjou, M.P. Chenard, J.M. Reimund, J.N. Freund (Caen Cedex, France)

P127

Environmental factors in an inception cohort of IBD patients with a steep increase of incidence from 2003-2005 in Copenhagen County and City: A DCCD study

M. Elkjaer, N. Petersen, L. Riis, T. Stenbaek Hansen, E. Knudsen, I. Bak Andersen, T. Priø, P. Nørregaard, F. Moesgaard, I. Vind, F. Bendtsen, P. Munkholm (Copenhagen, Denmark)

P128

Polymorphisms of cytokine genes in determining disease susceptibility and phenotype in Crohn's disease (CD)

M. Brito, P. Ferreira, C.S. Guerreiro, L. Tavares, P.M. Santos, J.P. Silva, I. Claro, M. Cravo (Lisboa, Portugal)

P129

The modulating effect of diet on disease activity in patients with Crohn's disease (CD) depends on the genotype for cytokines genes

M. Cravo, C.S. Guerreiro, P. Ferreira, L. Tavares, P.M. Santos, J.P. Silva, I. Claro, M. Brito (Lisboa, Portugal)

P130

Awareness of Crohn's Disease and Ulcerative Colitis in the Austrian Population

S. Angelberger, H. Vogelsang, G. Novacek, W. Miehsler, C. Dejaco, A. Gangl, W. Reinisch (Vienna, Austria)

P131

NOD 2/CARD 15 gene polymorphisms in Serbian patients with Crohn's disease: Genotype-phenotype analysis

M. Nedeljkovic Protic, N. Jojic, D. Bojic, A. Milovanovic, S. Pavlovic, M. Krstic (Belgrade, Serbia)

P132

Angiotensin-Converting Enzyme (ACE) insertion/deletion (I/D) gene polymorphism in inflammatory bowel diseases

L. Spina, S. Saibeni, T. Virgilio, A. Folcioni, G. Borsi, C. Ciscato, R. de Franchis, M. Cugno, M. Vecchi (San Donato Milanese (Mi), Italy)

P133

Lymphangiogenesis in Crohn's disease

F. Pedica, P. Baccharini, C. Ligorio, P. Tonelli, M.P. Foschini (Bologna, Italy)

P134

Allelic variants of the multidrug resistance gene (MDR1/ABCB1) and response to corticosteroid therapy in patients with inflammatory bowel disease

S. Cukovic-Cavka, N. Bozina, M. Brinar, K. Grubelic-Ravic, Z. Krznaric, M. Rojnic-Kuzman, N. Rustemovic, T. Brkic, R. Pulanic, J. Sertic, B. Vucelic (Zagreb, Croatia)



P135

Influence of MDR1 polymorphisms on short-term and long-term response to Infliximab

R. Donoval, O. Slanar, D. Duricova, M. Lukas (Prague, Czech Republic)

P136

Contribution of genetic and environmental factors in the pathogenesis of Crohn's disease in a large family with multiple cases

M. Joossens, M. Simoens, S. Vermeire, X. Bossuyt, K. Geboes, P. Rutgeerts (Leuven, Belgium)

P137

Colectomize or not in ulcerative colitis– that's the question

T. Bernklev, O. Høie, C. Solberg, M. Henriksen, F. Wolters, R. Stockbrügger, E. Langholz, P. Munkholm, M. Vatn, B. Moum (Oslo, Norway)

P138

Are there other factors explaining why UC-patients with normal colonoscopy still report IBD-related symptoms?

T. Bernklev, M. Henriksen, J. Jahnsen, Ø. Palm, M. Vatn, B. Moum (Oslo, Norway)

P139

Genetic association of CARD15 variants with Crohn's disease in the Czech population

M. Lenicek, O. Hradsky, O. Cinek, M. Lukas, J. Bronsky, M. Bortlik, R. Donoval, L. Vitek (Prague, Czech Republic)

P140

Geographical distribution of inflammatory bowel disease (IBD) in France at the scale of job area

V. Nerich, E. Monnet, A. Weill, V. Vanbockstael, G.R. Auleley, H. Allemand, C. Balaire, P. Duboz, F. Carbonnel (Besancon, France)

P141

Epidemiology of IBD in Croatian Children

I. Hojsak, Z. Misak, S. Kolacek (Zagreb, Croatia)

P142

Ulcerative colitis: disease recurrence in a population based European cohort followed for 10 years

O. Høie, F.L. Wolters, G. Aamodt, C. Solberg, T. Bernklev, S. Odes, I.A. Mouzas, M. Beltrami, E. Langholz, R.W. Stockbrügger, M. Vatn, B.A. Moum (Arendal, Norway)

P143

Adherence to medication in inflammatory bowel disease patients

P. Bertomoro, M.G. Vettorato, K. Mazzocco, R. Rumiat, G.C. Sturniolo, R. D'Inca (Padua, Italy)

P144

Regularized least squares classifiers may predict Crohn's disease from profiles of single nucleotide polymorphisms

A. Latiano, A. D'Addabbo, O. Palmieri, F. Bossa, R. Maglietta, G. Corritore, T. Latiano, A. Andriulli, N. Ancona, V. Annese (San Giovanni Rotondo (Fg), Italy)

P145

Does health-related quality of life change in follow-up in ulcerative colitis and Crohn disease?

M.L. Høivik, C. Solberg, J. Jahnsen, T. Bernkelv, B. Moum (Oslo, Norway)



P146

Evaluation of nuclear pregnane X receptor (NR1I2) in pediatric patients with IBD

M. Lacher, S. Berkholz, M. Kabesch, D. v. Schweinitz, R. Kappler, S. Koletzko (München, Germany)

P147

Genetic markers and the risk of complicated disease behaviour in Crohn's disease patients

L. Henckaerts, I. Verstreken, K. Van Steen, R. Vlietinck, P. Rutgeerts, S. Vermeire (Leuven, Belgium)

P148

Multidrug resistance 1 gene polymorphism and susceptibility to inflammatory bowel disease

S. Ardizzone, G. Maconi, A. Russo, E. Colombo, A. Cassinotti, C.M. Penati, M.L. Tenchini, G. Bianchi Porro (Milan, Italy)

P149

NOD2/CARD15 gene mutations and risk of re-operation in Crohn's disease patients

G. Maconi, E. Colombo, G.L. Sampietro, F. Lamboglia, M. Daperno, S. Ardizzone, R. D'Inca, A. Cassinotti, G.C. Sturniolo, G. Bianchi Porro (Milan, Italy)

P150

Pregnancy outcome and fertility in inflammatory bowel disease is influenced by disease phenotype

C.W. Lees, R.E. Gailer, N.C. Johnston, P. Warner, H.O. Critchley, J. Satsangi (Edinburgh, United Kingdom)

P151

Lipopolysaccharide-induced cytokine production: the effects of Certolizumab Pegol, Etanercept, Adalimumab and Infliximab

G. Fossati, D. Brown, A. Nesbitt (Slough, United Kingdom)

P152

Lack of placental transfer and accumulation in milk of an anti-TNF PEGylated Fab' fragment in rats

S. Stephens, D. Brown, A. Nesbitt, R. Foulkes (Slough, United Kingdom)

P153

Expression of toll-like receptors 2, 4 and CD14 in human intestinal mucosa from patients with Inflammatory Bowel Diseases (IBD)

L. Frolova, P. Drastich, K. Klimesova, P. Rossmann, H. Tlaskalova-Hogenova (Prague, Czech Republic)

P154

Intestinal Immune-Modulation by Enteric Glia involves signaling via NOD receptor and nuclear factor-kappaB in Rat

E. Hollenbach, M. Zöller, W. Stremmel, M. Vieth, M. Neumann, P. Malfertheiner, A. Rühl (Leipzig, Germany)

P155

Influence of intestinal bacteria on colitis developing in SCID mice reconstituted with CD4+CD45RBhigh T cells on the changes of tight junctions (TJs) and Paneth cells

R. Stepankova, F. Powrie, O. Kofronova, H. Kozakova, T. Hudcovic, T. Hrnčir, H. Tlaskalova-Hogenova (Novy Hradek, Czech Republic)

P156

Protective effect of E. coli strain Nissle 1917 and E. coli strain O83 in dextran sulphate sodium-induced colitis in mice is dependent on the route of the application



T. Hudcovic, R. Stepankova, T. Hrnecir, H. Kozakova, M. Schwarzer, H. Tlaskalova-Hogenova
(Novy Hradek, Czech Republic)

P157

Transforming growth factor-beta blockade up-regulates T-bet expression and increases proinflammatory cytokines and stromelysin-1 (MMP-3) in normal colonic mucosa

A. Di Sabatino, L. Rovedatti, G. Monteleone, T.T. MacDonald (Pavia, Italy)

P158

Metallothionein silencing in intestinal epithelial cells results in impaired chemoattractant activity

A. Waeytens, D. Laukens, S. Janssens, H. Peeters, P. Rottiers, C. Cuvelier, M. De Vos
(Ghent, Belgium)

P159

Azoxymethane-induced colon cancer development in mouse model of human IBD

K. Klimesova, P. Rossmann, M. Kverka, O. Kofronova, O. Benada, L. Frolova, H. Tlaskalova - Hogenova (Prague, Czech Republic)

P160

Mucosal release of phagocyte-specific S100 proteins is strongly enhanced during active inflammatory bowel disease

D. Foell, Z. Ren, H. Wittkowski, J. Roth, T. Borody, R. Clancy (Muenster, Germany)

P161

Disturbed expression of alpha-defensins and tissue inhibitor of matrix metalloproteinase-1 in neutrophils of Crohn's disease patients

S. Bogaert, H. Peeters, D. Laukens, M. de Vos (Ghent, Belgium)

P162

Visilizumab targets multiple immune-mediated pathways

V. Vexler, J. Sheridan, T. Tsao, J. Li, L. Zeng, Y. Mu, K. Lin, J. Shi, J. Woo (Fremont, USA)

P163

Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease

F. Scaldaferrri, M. Sans, C. Graziani, R. De Cristofaro, S. Vetrano, B. Gerlitz, A. Repici, A. Gasbarrini, A. Malesci, J. Panes, B.W. Grinnell, S. Danese (Rome, Italy)

P164

Infliximab treatment decreases serum osteoprotegerin concentration in patients with Crohn's disease

P. Miheller, G. Múzes, K. Rácz, A. Blázovits, L. Herszényi, P. Lakatos, Z. Tulassay
(Budapest, Hungary)

P165

Inflammatory bowel disease in CGD reproduces the pathological features of Crohn's disease

D.J.B. Marks, K. Miyagi, F.Z. Rahman, N. Grosvenor, S.L. Bloom, A.W. Segal
(London, United Kingdom)

P166

Lactobacillus precolonization of SCID mouse mothers protect their offspring against the inflammation induced by dextran sulphate sodium treatment

H. Kozakova, T. Hudcovic, T. Hrnecir, R. Stepankova, H. Tlaskalova-Hogenova, B. Cukrowska
(Novy Hradek, Czech Republic)



P167

Characterization of the neurochemical and neuromuscular adaptations in a rat model of ulcerative colitis

M. Auli, Y. Nasser, W. Ho, C.M. Keenan, J.F. Burgueño, C. Romero, K.A. Sharkey, E. Fernandez (Bellaterra, Barcelona, Spain)

P168

Partial replacement of dietary fat with MCT improves the course of the disease and enhances the apoptosis of colonic CD3+ cells in IL-10(-/-) colitic mice

E. Pedrosa, J. Manyé, V. Lorén, I. Ojanguren, L. Fluvià, J.M. Hernández, G. Rogler, E. Cabré, F. Fernández-Bañares, M.A. Gassull (Badalona, Spain)

P169

Treatment with Lactobacillus Fermentum (LF) after the induction of experimental colitis accelerates the healing of colonic damage in BALB/C mice

J. Manyé, V. Lorén, E. Pedrosa, I. Ojanguren, E. Cabré, R. Bartolí, J. Xaus, E. Domènech, M.A. Gassull (Badalona, Spain)

P170

CD3+CD4+ lymphocytes show differences in steroid-induced apoptosis ex vivo depending on the proliferation activating stimulus

J. Manyé-Almero, E. Pedrosa, V. Lorén, E. Domènech, M. Mañosa, L. Fluvià, A. Rio, E. Cabré, M.A. Gassull (Badalona, Spain)

P171

Pretreatment with Lactobacillus Fermentum (LF) decreases the short-term severity of experimental colitis in BALB/C mice

V. Lorén, J. Manyé, E. Pedrosa, I. Ojanguren, E. Cabré, R. Bartolí, J. Xaus, E. Domènech, M.A. Gassull (Badalona, Spain)

P172

The neutrophil respiratory burst is generally preserved in Crohn's disease, but diminished by cigarette smoking

M. Harbord, D. Marks, S. Bloom (London, United Kingdom)

P173

Critical role of epithelial Junctional adhesion molecule-A in experimental colitis

S. Vetrano, F. Tognoli, E. Borroni, N. Polenterutti, M. Corada, M.R. Cera, V. Arena, A. Malesci, M. Locati, R. Rescigno, E. Dejana, S. Danese (Milan, Italy)

P174

Critical role of MAP kinases in governing lymphocyte adhesion to and migration across microvasculature in inflammatory bowel disease

M. Sans, F. Scaldaferri, S. Vetrano, T. Stefanelli, C. Graziani, V. Arena, A.E. Potenza, A. Repici, A. Malesci, S. Danese (Barcelona, Spain)

P175

Role of TGF-Beta1 and IGF-1 in Crohn's disease recurrence after ileo-colonic resection

M. Scarpa, M. Bortolami, S. Morgan, A. Kotsafi, S. Ferraro, C. Ruffolo, R. D'Inca, L. Polese, M. Barollo, D. D'Amico, G. Sturniolo, I. Angriman (Padova, Italy)

P176

C-reactive protein (CRP), a novel adipocytokine overexpressed in mesenteric fat in Crohn's disease



F. Gonzalez, L. Peyrin-Biroulet, C. Rousseaux, X. Thuru, C. DeCourcelle, L. Gambiez, A. Saudemont, C. Neut, L. Pénicaud, J.B. Saulnier, J.F. Colombel, P. Desreumaux (Lille, France)

P177

Mycobacterial HSP60 and HSP70 prevents the severe form of acute DSS colitis in Balb/c mice

M. Kverka, Z. Zakostelska, H. Tlaskalova-Hogenova, R. van der Zee, W. van Eden

(Prague, Czech Republic)

P178

Early Crohn's disease shows high levels of remission to therapy with Adalimumab: sub-analysis of CHARM

S. Schreiber, W. Reinisch, J.-F. Colombel, W. Sandborn, D. Hommes, J. Li, J. Kent, P. Pollack (Parsippany, USA)

P179

Mesenteric lymph nodes play an important role in supplying Crohn lesions with activated T-cells

M. Eberhardson, M. Karlsson, P. Karlén, K. Lindberg, O. Broström, O. Winqvist, M. Thörn (Stockholm, Sweden)

P180

Peripheral blood dendritic cells enumeration in inflammatory bowel disease patients during Infliximab treatment

M. Principi, A. Castellaneta, N. De Tullio, A. Pisani, A. Di Leo, A. Francavilla (Bari, Italy)

P181

Free IL-18 in Crohn's disease: is the target suitable for a therapeutic intervention with IL-18 binding protein? Validation of the expression of free IL-18 in sera of active patients

S. Ardizzone, A. Cassinotti, O. Della Casa Alberighi, L. Leone, A. Massari, G. Maconi, E. Radice, E. Bareggi, M. Bosani, E. Colombo, V. Imbesi, G. Bianchi Porro (Milan, Italy)

P182

Enhanced expression of noncanonical Wnt 5a in the colonic mucosa of patients with ulcerative colitis

A. Buda, R. D'Inca', S. Voltan, D. Pizzuti, D. Checchin, A. Garribba, M. Pignatelli, G.C. Sturniolo (Padova, Italy)

P183

A functional role for interleukin-21 in promoting the synthesis of the T cell chemoattractant, MIP-3alpha, by gut epithelial cells

R. Caruso, D. Fina, I. Peluso, C. Stolfi, M.C. Fantini, F. Caprioli, T.T. MacDonald, F. Pallone, G. Monteleone (Rome, Italy)

P184

NF-kB controls the expression of flip, an inhibitor of FAS-mediated apoptosis, in Crohn's disease lymphocytes

F. Caprioli, D. Fina, R. Caruso, I. Peluso, M.C. Fantini, C. Stolfi, G. Sica, A. Rizzo, S. Janssen, L. Biancone, F. Pallone, G. Monteleone (Rome, Italy)

P185

Increased gut plasmacytoid dendritic cells in acute ulcerative colitis - key mediators of immunity and inflammation?

S.C. Ng, S. Plamondon, M.A. Kamm, S.C. Knight, A.J. Stagg (London, United Kingdom)

P186



Intestinal cytokine production by dendritic cells in acute ulcerative colitis - an immunoregulatory role?

S.C Ng, S. Plamondon, M.A. Kamm, S.C. Knight, A.J. Stagg (London, United Kingdom)

P187

Expression profile of peripheral regulatory T cells in IBD on the self-developed Human TReg Chip

J. Maul, S. Pfortner, J. Buer, R. Geffers, R. Duchmann (Berlin, Germany)

P188

Luminal antigens access not only MHC II but also MHC I pathways in multivesicular late endosomes of intestinal epithelial cells - In vivo Study in Crohn's ileitis

G. Hundorfean, S. Strobel, K.P. Zimmer, A. Gebert, D. Ludwig, J. Büning (Lübeck, Germany)

P189

Visfatin - a novel member of the adipocytokine family is activated in inflammatory bowel disease

A. Moschen, A. Kaser, B. Enrich, H. Niederegger, H. Tilg (Innsbruck, Austria)

P190

In vitro effects of TNF-alpha and interleukin (IL)-10 (IL-10) production by activated peripheral blood mononuclear cells (PBMCs) from healthy controls and Crohn's disease patients by different lipid emulsions for parenteral use with a various n-6/n-3 poly

B. Dupont, S. Allouche, R. Gloro, B. Sola, J. M. Reimund (Caen Cedex, France)

P191

Selective induction of Crohn's disease (CD) and ulcerative colitis (UC) lamina propria mononuclear cells (LPMC) apoptosis by probiotics: involvement of bacterial sphingomyelinase (SMase)

S. Angulo, S. Danese, N. Pultz, M. Grazia Cifone, A. Morales, C. De Simone, J.C. Fernandez-Checa, J. Panes, C.J. Donskey, C. Fiocchi, M. Sans (Barcelona, Spain)

P192

Preliminary study on bacterial translocation in serum of patients with inflammatory bowel disease.

A. Gutiérrez, R. Francés, J. Such, M. Garmendia, M. Ndongo, R. Jover, M. Pérez-Mateo (Alicante, Spain)

P193

Pro-inflammatory effect of Helicobacter pullorum on human intestinal cell lines

D. Laharie, C. Varon, A. Duriez, F. Zerbib, A. Menard, P. Lehours, F. Megraud (Pessac, France)

P194

hPepT1 selectively transports muramyl dipeptide but not Nod1-activating muramyl peptides

S. Vavricka, M. Ismail, G. Kullak-Ublick, M. Fried, D. Mengin-Lecreulx, S. Girardin (Zurich, Switzerland)

P195

The presence of escherichia coli bacteriophages in human stool of patients with inflammatory bowel disease

M. Lusiak - Szelachowska, B. Weber - Dabrowska, A. Górski, A. Annabhani, K. Blachut, L. Paradowski (Wroclaw, Poland)

P196



Cytomegalovirus blocks apoptosis in patients with active ulcerative colitis and colonic viral infection

R. Vega, H. Keshaw, E. Domenech, I. Ojanguren, M.A. Gassull, A. Forbes, R. Day
(London, United Kingdom)

P197

Is Escherichia coli more than a commensal bacterium in the intestinal mucosa of Crohn's Disease patients?

M. Martinez-Medina, X. Aldeguer, F. Gonzalez-Huix, D. Acero, M. Lopez-Siles, L.J. Garcia-Gil
(Girona, Spain)

P198

Galectin-4 induces T cell apoptosis and ameliorates intestinal inflammation in an experimental model of murine colitis

D. Paclik, C. Guzy, U. Berndt, B. Wiedenmann, A. Dignass, H.J. Gabius, A. Sturm (Berlin, Germany)

P199

Entero-hepatic Helicobacter species and postoperative recurrence of Crohn's disease: preliminary results of a prospective case-control study

D. Laharie, C. Asencio, P. Bulois, A. Bourreille, J. Moreau, P. Bonjean, D. Lamarque, E.A. Pariente, J.C. Soule, A. Charachon, F. Megraud, F. Zerbib (Pessac, France)

P200

Faecal bacterial DGGE profiles of Crohn's disease patients are different from those of their healthy first degree relatives and matched healthy controls

M. Joossens, T. Vanhoutte, V. De Preter, K. Van Steen, L. Henckaerts, G. Huys, K. Verbeke, P. Vandamme, P. Rutgeerts, S. Vermeire (Leuven, Belgium)